#USA #Plano #Bimini Health #Puregraft #Dermapose

Bimini Health Tech Achieves EU-MDR Certification

Bimini Health Tech, a prominent provider of medical technologies focused on women's health, has made a significant announcement regarding its recent achievement in obtaining the EU Medical Device Regulation (EU-MDR) certification. This milestone marks an essential progression in the company's ongoing efforts to expand its footprint in the European market.

Founded in 2013, Bimini Health Tech has established itself as a leader in the women's health sector, driven by decades of expertise in developing, acquiring, and marketing innovative products aimed at delivering superior solutions to patients and healthcare professionals. With a portfolio that includes Puregraft systems, Essence Acellular Dermal Matrix, and Dermapose fat harvesting and sizing systems, Bimini is dedicated to enhancing the quality of care available to women worldwide.

Significance of the EU-MDR Certification

The certification is particularly relevant as it allows Bimini to diversify its product approvals in Europe, focusing on its Puregraft and Dermapose collections. Brad Conlan, CEO of Bimini Health Tech, expressed enthusiasm over this achievement, stating, "We are thrilled about the EU-MDR certification for Bimini and the expansion of our product approvals for our two fat transfer product families, Puregraft and Dermapose. This milestone reflects our unwavering commitment to providing high-quality, innovative technologies for patients and physicians globally."

The global market for fat transfer procedures has seen a significant increase, with the latest survey from the International Society of Aesthetic Plastic Surgery (ISAPS) indicating a 19.2% rise in fat transfers compared to the previous year, totaling over 940,000 procedures worldwide. Bimini Health Tech's products are poised to capture a substantial share of this growing market.

Overview of Bimini’s Fat Transfer Products

Puregraft®: This product line is designed for quick and efficient fat filtration and cleaning in large quantities within a closed system. Puregraft employs patented dialysis filtration technology that gently separates viable fat tissue from blood, oil, and waste fluids. As a result, it produces a high concentration of healthy, viable fat cells. The Puregraft line includes several models, such as Puregraft 50, Puregraft 250, Puregraft 850, and the newly FDA 510(k) approved Puregraft SYNC® technology. Currently, these products are available in over 50 countries worldwide.

Dermapose®: This technology specializes in smaller volume fillers and rejuvenation treatments, enabling surgeons to extract, cleanse, size, and inject micro-fat within a singular closed system. The Dermapose suite is focused on supporting efficient processing and reinjection of fat tissue, while promoting versatility and consistency in procedures. Post-EU MDR certification, Dermapose is authorized for use in the United States, the European Union, Japan, Brazil, Australia, Canada, and Saudi Arabia.

Commitment to Innovation and Research

Bimini Health Tech's commitment to innovation is underscored by its extensive portfolio, which includes over 100 patents, 20 device approvals, and more than 25 scientific publications. To date, Bimini’s products have been utilized in over 1.5 million procedures worldwide, affirming the reliability and efficacy of their technologies.

As Bimini Health Tech continues to expand its global presence, the recent achievement of EU-MDR certification not only enhances its credibility but also restores confidence in its mission to advance women's health through innovative medical solutions. For more information on Bimini Health Tech and their product offerings, visit Bimini Health Tech's official website.